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Controlled clinical trials have high internal validity but
suffer from difficulties in external validity. This study evalu-
ates the generalizability of the results of a controlled clinical
trial on rapid detoxification in the everyday clinical practice
of two addiction treatment centers. The results show that
rapid detoxification in everyday practice differs with regard
to patient characteristics, enrolment, and completion rates
(86.8% vs. 100%). However, abstinence rates after rapid
detoxification in the controlled clinical trial (61.8%) were
generalizable to everyday clinical practice (59.0%). Imple-
mentation factors that may have influenced the results, such
as referral problems and treatment delivery, are discussed.
(Am J Addict 2010;19:283–290)
INTRODUCTION
Randomized controlled trials (RCTs) are considered as
the “gold standard” for assessing treatment efficacy and the
impact of healthcare interventions.1 RCTs are particularly
successful in reducing all kinds of biases and increasing
internal validity.2–6 However, controlling for factors opti-
mizing internal validity can reduce the clinical relevance
and external validity (generalizability) of the findings of an
RCT study. For instance, controlling for treatment delivery
and outcome measurements could limit the conclusions
of the RCT in their range of application and treatment
programs. Second, inclusion and exclusion criteria are ap-
plied to control for sample characteristics, whereby large
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segments of the general patient population are excluded.
Another controlling factor is the optimized conditions (eg,
research clinic, experienced and highly classified clinicians,
no time constraints) through which the RCT may be un-
representative of regular clinical practice.7–10 Apart from
this, the participant’s awareness of participating in an RCT
can affect the treatment results, as does the availability of
treatment preference.11,12
All in all, RCTs create an “ideal condition” to measure
the efficacy of an intervention, but it is unclear if the in-
tervention is equally effective under normal conditions.13
Making evidence from scientific studies available to clini-
cal practice is expected to improve the quality of care. This
expectation is not always realized due to the complexity of
healthcare.14 As Black10 states, “Randomized trials gener-
ally offer an indication of the efficacy of an intervention
rather than its effectiveness in everyday practice.” Victoria
et al.2 report two types of effect modification that must
be considered when the generalizability of RCT results is
assessed: the first consists of factors affecting the dose of
the intervention (eg, changes in providers, promotion of
compliance); the second consists of lower response due to
the presence of other factors (eg, other population crite-
ria, other cointerventions, missing a critical cofactor, other
causes of the outcomemeasure).Another factor to consider
is treatment integrity, being the extent to which an inter-
vention is implemented as intended or planned.15 This later
function includes treatment adherence (how often the in-
tended therapy is or is not provided) and competence (how
skillfully or poorly the treatment techniques are applied).16
Rapid detoxification has been shown to be an effective
approach to the management of opioid withdrawal.17,18 In
the Netherlands, an RCT was conducted in which the add-
on effect of general anesthesia was examined during rapid
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detoxification induced by naltrexone.19 General anesthesia
proved to be equally effective, although with less safety and
higher costs. This was also confirmed by other studies.20,21
In a reevaluation according to a naturalistic design, it
proved that rapid detoxification produced convincing com-
pletion and abstinence rates at 1, 10, and 16 months. Absti-
nent patients displayed significantly improved health when
compared to their baseline health state and to those in the
relapsed group.22 As professionals and the Dutch Ministry
of Health were convinced of the effectiveness of the rapid
detoxification treatment, its implementation without anes-
thesia was started by clinical addiction treatment centers in
2003. However, it was not clear if the results of rapid detoxi-
fication from a controlled clinical trial could be transferred
to everyday clinical practice. Thus, in this study we sought
to determine the effectiveness of rapid opioid detoxification
without anesthesia in two clinical addiction treatment cen-
ters in the Netherlands (implementation study), compar-
ing the treatment outcomes with those from the previously
mentioned controlled clinical trial.
Specifically, the goals of our study were to compare the
results between the controlled clinical trial and the imple-
mentation of the same treatment protocol in everyday clin-
ical practice on
(1) patient characteristics;
(2) patient enrolment and completion rates;
(3) validity of self-reported opioid use; and
(4) abstinence rates at 1-month follow-up.
Some implementation factors that could possibly influ-
ence the results are mentioned in the “Discussion” section.
METHOD
Study Design
This study comprises an observational evaluation of
rapid detoxification in clinical practice (the implementa-
tion study) and a comparison of the treatment outcomes
with those of a previously published controlled clinical trial
of rapid detoxification (the controlled clinical trial). The
implementation study was conducted from June 2003 to
August 2007. It was approved by the Dutch Ethical As-
sessment Committee for Experimental Investigations on
People. We chose to compare the outcomes of the imple-
mentation study to those of the controlled clinical trial be-
cause the latter study provided data allowing comparison
with regard to the type of addiction treatment centers, the
patient populations, and the rapid detoxification protocol.
The controlled clinical trial was conducted from Septem-
ber 1999 to August 2001 to determine whether rapid detox-
ification under general anesthesia results in higher levels of
opioid abstinence than rapid detoxification without anes-
thesia. Only those patients treated without general anesthe-
sia were taken into account for the purposes of outcome
data comparison.
Patients
Patients were recruited on a voluntary basis. During the
implementation study, opioid-dependent patients from five
addiction treatment centers (Novadic, IrisZorg, Parnassia,
Jellinek, andKentron)were recruited for participation. Two
centers provided the treatment (Novadic, IrisZorg) if the
patients met the following criteria: diagnosed as opioid-
dependent according to DSM-IV criteria, expressed the
clear wish to become abstinent, were over 18 years of age,
and had at least one nonopioid user in their social network.
Exclusion criteria were severe somatic diseases or psychi-
atric disorders, pregnancy, and doubts about the patient’s
willingness to cooperate. The doubts were based on the pa-
tient’s record of showing up at the intake appointments.
Dependence on other drugs or current drug abuse was not
an exclusion factor. Following a complete description of
the study to the subjects, written informed consent was
obtained.
During the controlled clinical trial, patients from four
addiction treatment centers (Novadic, Jellinek, Parnassia,
and Kentron) were recruited for participation. Three cen-
ters provided the treatment (Novadic, Parnassia, and Ken-
tron) if theymet the criteria described earlier. In addition to
the inclusion criteria described earlier, two more inclusion
criteria were applied for the controlled clinical trial, namely
being familiar with the Dutch language and having made
several previous unsuccessful attempts to abstain.
Enrolment
Patients interested in detoxification during the imple-
mentation study were informed about rapid detoxification
by a professional responsible for assessment and referral.
Those meeting the screening criteria underwent examina-
tion by a physician, who also took their medical history,
to exclude individuals with severe somatic and psychiatric
disorders. The assessment and referral committee made the
final decision on whether a patient would be eligible for
rapid detoxification and put him or her on the waiting list.
On the day of admission to the treatment center, the pa-
tients were once again examined by a physician.
Compliance for the sake of enrolment was more pro-
moted in the controlled clinical trial than in the implementa-
tion study by engaging research assistants during the assess-
ment and referral procedure and offering the prospect of
bypassing the waiting lists. The assistants were very active
in the recruitment, as they received incentives for enrolling
patients. Unlike the clinical trial, the implementation study
did not provide staff incentives to encourage patient
enrolment.
Treatment Protocol
The treatment protocol for the implementation studywas
exactly the same as that for the controlled clinical trial.
In general, the program for rapid detoxification took 8
days—one for admission, three for detoxification, three for
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recovery, and one for discharge.Detoxificationwas induced
on the second day by administering an opioid antago-
nist (naltrexone). Naltrexone was given orally at a dose of
12.5mg (detoxification day 1), 25mg (detoxification day 2),
and 50 mg for the next 5 days. During the three detoxifica-
tion days, the patients were treated for signs and symptoms
of withdrawal according to a fixed schedule (see De Jong et
al.19 for a detailed overview). During the 3 days of recov-
ery, the patients were provided with a symptom-triggered
treatment.
After discharge, the patients were treated as usual by the
addiction care center. Aftercare consisted of a minimum
of 3 months of naltrexone intake with supervision by a
physician. This differed from the controlled clinical trial in
which all patients followed the Community Reinforcement
Approach protocol consisting of 23 sessions administered
by physicians and psychosocial therapists.
Implementation Interventions
The implementation study applied the following inter-
ventions:
Informing patients, healthcare professionals, and others.
To inform patients and members of the general popula-
tion, the availability of the new treatment was announced
in a press release, in local and free newspapers, and on the
Internet. Brochures and posters were distributed among
patients in methadone programs, and information sessions
were given on request. Letters, brochures, and e-mails were
sent to healthcare professionals at the participating addic-
tion centers to inform them of the possibility for treatment
and to educate them about the diagnostic criteria for rapid
detoxification and the enrolment procedure.
Informing healthcare professionals involved in the assess-
ment and referral procedure. Detailed educational sessions
and a conference on rapid detoxificationwere organized for
healthcare professionals working with opioid-dependent
patients. Protocols and checklists were made available to
the healthcare professionals responsible for the assessment
and referral procedure, to members of the committee for
assessment and referral, and to the administrator of the
waiting list. All physicians were trained with regard to the
medical screening, the study inclusion and exclusion crite-
ria, and the side effects of naltrexone. They were also pro-
vided with detailed information on the rapid detoxification
procedure and naltrexone maintenance.
Informing and training healthcare professionals on the new
treatment. Nurses and physicians from the detoxification
unit were trained in the rapid detoxification procedure for
which detailed protocols were available. They received in-
formation about the side effects of medication used dur-
ing rapid detoxification, about withdrawal symptoms, and
about possible complications that may occur during rapid
detoxification.Additional nurse trainingwas given in blood
pressure measurement, medication injection, and observa-
tion for dehydration. A nurse experienced in rapid detoxi-
fication supported the detoxification unit during the three
detoxification days.
The implementation interventions were highly compa-
rable for both studies, except for the assessment and refer-
ral procedure. Because special assignment was available in
the controlled clinical trial (see “Enrolment” section), the
healthcare professionals were only informed about the in-
clusion and exclusion criteria for patients and how to refer
them to a research assistant.
Outcome Measures
Research assistants assessed patients at baseline (admis-
sion) and at 1-month follow-up. We compared the charac-
teristics of the patients, patient enrolment, and treatment
completion rates across the two studies. Patients were di-
vided into four groups: included, not started, drop-out ver-
sus completed, and lost to follow-up (Fig. 1). Because of
the considerable amount of missing urine specimens in the
implementation study and the possibility of underreport-
ing of opioid use by self-report, we carried out a check
on agreement between self-report and urine test results to
measure the validity of self-report. After that, an overall ab-
stinence rate at 1-month follow-up was computed for those
patients who had started rapid detoxification (regardless of
completion).
Treatment results were measured with the EuropAd-
diction Severity Index (EuropASI) and urine specimens.
The EuropASI measures the severity of addiction in eight
domains: physical health, work/education/income, alco-
hol, drugs, legal problems, family/social relationships,
psychological/emotional complaints, and gambling. The
EuropASI was used for treatment entry scores, but also for
self-report of opioid use at 30 days after detoxification.23
Urine specimens taken 30 days after detoxification were
analyzed for psychoactive substances by an approved lab-
oratory. Screening was performed on an Olympus AU 600
analyzer after immunoassays. The parameters screened
for, the specific techniques used, and the cut-off values
were as follows: for opiates—EMIT II, cut-off 300 ng/mL
morphine; for methadone—CEDIA, cut-off 100 ng/mL
EDDP.
Data Analysis
Differences in the baseline characteristics and in enrol-
ment, completion, and abstinence rates between the im-
plementation study and the controlled clinical trial were
analyzed with the χ2-test (Pearson) for categorical data
and the independent t-test for continuous data.
A check on agreement between self-report and urine
test results was carried out. Data from both studies was
combined to make more data available for comparison.
Opioid abstinence 1 month after detoxification was de-
fined as a self-report of no heroin, methadone, or other
opioid use in the last 30 days. If patients reported opioid
use or had a positive urine analysis for opioids 1 month
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FIGURE 1. Patient flow diagram.
after detoxification, they were defined as nonabstinent
(Table 2).
All statistical tests were 2-sided, with a p value of .05
or less considered to indicate statistical significance. The




Table 1 provides the sample characteristics of the two
studies. Patients in the implementation study were signif-
icantly older (38.4 vs. 36.0 years), had higher educational
levels (48.6% had secondary or higher education compared
to 22.3% in the controlled clinical trial), used less heroin in
the 30 days before admission (15.25 vs. 18.62), had lower
EuropASI drug severity (5.71 vs. 6.24) and family/social
severity scores (2.09 vs. 2.60), but had higher severity scores
for work/education/income (2.73 vs. 2.10).
Patient Enrolment and Completion Rates
Over a period of 40 months, 121 patients were admitted
for rapid detoxification in the implementation study. As
this study did not record patient interest in rapid detoxifi-
cation, it is unclear how many patients were interested in
or met the inclusion criteria for rapid detoxification. Four
patients (3.3%) did not start rapid detoxification: one be-
cause of the patient’s doubts, one because of anxiety, one
because of intoxication (even though this was not an ex-
clusion factor), and one for unknown reasons. Twelve pa-
tients (9.9%) did not complete the 3 days of detoxification
(drop-outs) but 105 (86.8%) did (completers). No signifi-
cant differences were found on any demographic character-
istic between drop-outs and completers. The mean number
of treatment days of all 117 patients who started detoxifi-
cation was 7.19 (SD = 2.06), ranging from 2 to 14 days.
In the rapid detoxification group of the controlled clin-
ical trial, a total of 135 patients were enrolled during
23 months. All 135 completed the 3 days of detoxification.
The rates of completion were significantly different (χ2 =
19.04; p < .00) between the implementation study (86.8%)
and the controlled clinical trial (100%).
Validity of Self-reported Opioid Use
Defining opioid abstinence in terms of both negative
self-report of opioid use and negative urine analysis was
not possible for 49.2% of the patients. Given the possibility
of underreporting, we carried out a check on agreement
between self-report and urine test results. Data from both
studies was combined tomakemore data available for com-
parison. Of both studies, only three patients (11.1%) with
a positive urine analysis reported no opioid use. Thus, self-
reported opioid use seems to be a valid method to define
opioid abstinence (Table 2).
Abstinence Rates
Of the 121 patients in the implementation study, 45
(37.2%) were lost to follow-up at 1month after rapid detox-
ification. Of the remaining 76 patients who started rapid
detoxification, 61.8% could be rated as abstinent, whereas
27 (35.5%) were nonabstinent and two had missing values
on self-report.
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TABLE 1. Baseline characteristics of patients by study
Controlled clinical
trial (n = 135)
Implementation
study (n = 121)
Statistical
Characteristics n n significance test
Age in years, mean (SD) 35.99 (6.50) 135 38.37 (6.42) 121 t = −2.95; <.01∗
Male (%) 81.5 135 81.0 121 χ2 = .01; .92






Marital status (%) 128 101 χ2 = 1.54; .46
Married 18.0 13.9
Never married 65.6 73.3
Divorced/widowed 16.4 12.9
Employment (%) 128 102 χ2 = 4.65; .10
Full time 55.5 44.1
Part time 8.6 16.7
Unemployed 35.9 39.2





Opioid use in years, mean (SD)
Mean age at first heroin use 19.87 (11.16) 124 18.01 (19.44) 104 t = .90; .37
Mean years of heroin use 12.14 (6.07) 125 12.13 (6.65) 104 t = .01; .99
Mean age at first methadone use 20.98 (21.17) 125 23.01 (20.85) 102 t = −.72; .47
Mean years of methadone use 7.35 (5.60) 125 7.75 (5.99) 103 t = −.51; .61
Opioid use in days, mean (SD)
Heroin use last 30 days 18.62 (11.76) 125 15.25 (12.45) 104 t = 2.10; .04∗
Methadone use last 30 days 23.61 (10.08) 126 22.38 (11.53) 104 t = .86; .39
Number of previous drug detoxification 2.94 (3.37) 126 3.15 (3.55) 99 t = −.46; .64
treatments, mean (SD)
EuropASI Severity scores, mean (SD)
Physical health 1.12 (1.40) 115 1.18 (1.55) 106 t = −.29; .77
Work, education, and income 2.10 (2.29) 115 2.73 (1.97) 105 t = −2.17; .03∗
Alcohol .88 (1.69) 120 .98 (1.61) 104 t = −.48; .63
Drugs 6.24 (1.07) 110 5.71 (1.13) 104 t = 3.48; < .01∗
Justice/police 1.65 (2.02) 116 1.78 (1.75) 105 t = −.52; .60
Family/social relations 2.60 (1.77) 112 2.09 (1.81) 105 t = 2.11; .04∗
Psychological/emotional problems 2.13 (1.92) 109 2.56 (2.04) 105 t = −1.60; .11
∗p-Value is statistically significant at the .05 level (2-tailed).
The controlled clinical trial had lost 18 (13.3%) pa-
tients at 1-month follow-up. The abstinence rate of the
remaining patients (59.0%) was comparable to and not
significantly different than that found for the implemen-
tation study. There were 43 nonabstinent controlled trial
patients (36.7%), and five patients had missing values on
self-report.
DISCUSSION
In this study we sought to determine the effectiveness
of rapid opioid detoxification in clinical addiction treat-
ment centers (implementation study) by comparing the
treatment outcomes with those from a controlled clin-
ical trial. As treatment results, we included the patient
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TABLE 2. Validity of self-report in the implementation study and the controlled clinical trial (n = 256)
Urine analysis
Negative Positive No data
∗
Total
Self-report opioid use last 30 days Negative 88† 3‡ 28† 119
Positive 15‡ 24‡ 20‡ 59
No data
∗
7§ 8‡ 63‖ 78
Total 110 35 111 256
∗No data is the result of missing data or no follow-up response for self-report; for urine analysis it is the result of not submitting a urine specimen.
† Defined as opioid abstinent.
‡ Defined as nonabstinent.
§ Missing values.
‖ Lost to follow-up.
characteristics, patient enrolment and completion rates, va-
lidity of self-reported opioid use, and abstinence rates at 1-
month follow-up. The results show that rapid detoxification
in everyday clinical practice differs with regard to patient
characteristics, enrolment, and completion rates. Opioid
abstinence rates after 1 month, however, were comparable
to those from the controlled clinical trial. Some implemen-
tation factors that may have influenced the results will be
discussed later.
Patient Characteristics
The first difference observed between the implementa-
tion study and the controlled clinical trial concerns the
characteristics of enrolled patients. Despite broadening the
inclusion criteria, some characteristics indicated less severe
impairment among the implementation study population.
This could not be explained by differences in environment.
The older age of patients in the implementation study could
be explainedby the lower percentage of youngopioid clients
during recent years and the older age of the general popu-
lation of opioid users in the Netherlands. Yet the age and
gender of the implementation study population was repre-
sentative of the opioid-dependent population in theNether-
lands (80% being male and 42 years old in 2006).24,25 For
patients in the controlled clinical trial, the drug problems
were more severe than in our implementation study. This
could be explained by exclusion of the criterion “several
previous unsuccessful attempts to become abstinent” in the
implementation study and the high motivation among the
research assistants to provide a promising treatment for
patients with chronic, severe drug problems. The other dif-
ferences might be explained by the complex assessment and
referral procedure of the implementation study. It may have
proven especially challenging for patients with more fam-
ily/social problems and lower educational levels, resulting
in higher drop-out rates before admission.
Enrolment
Considering the longer duration of the implementation
study, the lower enrolment of patients was striking. The
inclusion criteria could not have had a negative influence
on enrolment because they were less strict than in the
controlled clinical trial. The difference in enrolment could
probably be attributed to the participation of additional
healthcare professionals in the controlled clinical trial,10
the differences in intervention delivery, and the measures
taken to promote high compliance among patients.2 Com-
pliance for enrolment in the controlled clinical trial was
promoted by engaging research assistants in the assess-
ment and referral procedure. Patients in the implementation
study underwent the normal assessment and referral pro-
cedures, with their long waiting times and a good chance of
getting unclear information. In the implementation study,
rapid detoxification was not carried out continuously be-
cause of the required extra nurses and incurred additional
costs. It was difficult to find a balance between enrolment
and rapid detoxification delivery. In sum, the long waiting
times during assessment and referral and the decrease in
rapid detoxification delivery may have influenced the en-
rolment. As in the implementation study, the connection
between waiting time and the high rate of “lost” patients
has also been found in other studies, for example, Scheeres
et al.13
Completion Rates
Rapid detoxification in the controlled clinical trial ob-
tained 100% completion rates. During the implementation
study, 86.8% patients completed detoxification. This differ-
ence may be explained by the subject’s and/or clinician’s
beliefs and treatment preferences and by the nature of the
treatment offered.10,26 The principle of treatment prefer-
ences is often cited to explain why there is so little dif-
ference in outcome between groups. But in our case, we
think that “treatment preference” could explain the 100%
completion rate during the controlled clinical trial and the
lower rate seen in clinical practice. During the controlled
clinical trial, there was a high level of expectation from and
a strong preference among the patients and clinicians for
both experimental treatment and control treatment. After
all, both options were “experimental” and thereby different
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from the regular methadone-tapering program (ie, patients
got a “special chance” to lead an abstinent life). By provid-
ing rapid detoxification in clinical practice with all of the
above-mentioned implementation problems, the “novelty”
may have been decreased and so may have the expectation
level. Nevertheless, the completion rate, although not as
high as during the controlled clinical trial, appeared to be
quite satisfactory. Other rapid detoxification studies have
found completion rates between 73% and 98%.20,27–33
Validity of Self-reported Opioid Use
Forhalf of the patients itwas not feasible todefine opioid
abstinence by the combination of negative self-report and
negative urine analysis. However, self-report did prove to
be a sufficiently reliable method for measuring abstinence
in the patient population of both studies.
Abstinence Rates at 1-Month Follow-up
Because of the lower completion rates and the lack of a
specified mechanism to ensure continuity of care between
detoxification and aftercare programs (lower treatment in-
tegrity), it was expected that the abstinence rates would
be lower in the implementation study than in the con-
trolled clinical trial. This was not the case, however. For
the patients in the implementation study who started rapid
detoxification, opioid abstinence rates at 1 month (61.8%)
were comparable to those from the controlled clinical trial
(59.0%). This might be the result of less severe impairment
in the implementation study population. Unfortunately,
follow-up response in the implementation study (62.8%)
was lower than in the controlled clinical trial (86.7%).
Strengths and Limitations of This Study
This study was a multicenter trial conducted in different
clinical addiction treatment centers in theNetherlands. The
implementation study was comparable to the controlled
clinical trial with regard to the type of addiction treatment
centers in which it was conducted, the patient populations
in terms of their environment, and the rapid detoxification
protocol utilized. Our study had the following limitations.
First, it is unclear how many patients were lost during the
assessment and referral procedures and why these patients
did not start treatment. The second limitation is the lower
follow-up response in the implementation study. Therewere
several reasons for the loss to follow-up, but unfortunately
we were not able to evaluate them in a consistent manner
because the research was subordinated to the clinical prac-
tice. Yet as the lower follow-up response is directly related
to the design of the study, we do not think this limitation
could influence our results in a negative way.
Conclusion
In conclusion, the results show that rapid detoxification
in everyday clinical practice differs from the controlled trial
outcomes with regard to patient characteristics, enrolment,
and completion rates. This could be the result of divergent
assessment and referral procedures and different aftercare
delivery. However, the completion rates for rapid detoxifi-
cation in the implementation study were still comparable
with those for the controlled clinical trial. Self-reported
opioid use proved to be a sufficiently reliable method for
ascertaining abstinence.
This study shows that abstinence rates after rapid detox-
ification in the controlled clinical trial were generalizable
to everyday clinical practice and that rapid detoxification
is an effective treatment option for opioid-dependent pa-
tients. In that light, assessment and referral procedures and
treatment delivery should be optimized to provide rapid
detoxification for more patients. Attention should be paid
to completion rates and continuity of care between detox-
ification and aftercare treatment programs to ensure these
positive results.
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